Overview of Flagil

Quick Facts

Property	Description
Active Ingredient	Metronidazole
Form	Oral (tablets, suspension), Intravenous, Topical/Vaginal
Pharmacological Class	Antimicrobial Agent (Antibiotic and Antiprotozoal)
Common Use	Targeting Anaerobic Bacterial and Protozoal Infections
Origin	Synthetic Compound (Nitroimidazole Derivative)

Flagyl is the established trade name for the active compound Metronidazole, a medication primarily defined as an antimicrobial agent that is clinically recognized for its efficacy against susceptible pathogens. As a prescription-only medicine, it is foundational in addressing specific bacterial and protozoal infections. The essential nature of Metronidazole is underscored by its status as an Essential Medicine.

What Type of Medicine Is Flagyl (Metronidazole)?

Metronidazole is chemically classified as a synthetic compound belonging to the nitroimidazole derivative chemical class. It functions uniquely as both an antibiotic and an antiprotozoal agent, a characteristic that allows for broad application against both bacteria and parasites. This dual role enables it to target two major categories of pathogenic organisms. Due to its efficacy against anaerobic pathogens, Metronidazole is a cornerstone therapy for infections caused by oxygen-intolerant bacteria.

Composition, Origin, and Available Forms

Metronidazole is a single-ingredient product known for its versatility in delivery; while similar nitroimidazole treatments exist, Metronidazole is distinguished by its extensive array of dosage forms tailored for both local and systemic administration. Available forms include oral tablets and capsules, an oral suspension, and an intravenous solution. For targeted local relief, specialized preparations such as topical creams/gels and vaginal suppositories are produced, allowing practitioners to precisely match the form to the infection site.

General Purpose and Mechanism of Action

The core purpose of Metronidazole is to effectively eliminate specific types of pathogenic microbes, notably anaerobic bacteria and protozoa. The drug operates through a principle of selective toxicity, targeting only the microorganisms that maintain the specific low-oxygen environment required to activate the medication. This activation directly damages the microbe's fundamental DNA structure, providing a rapid bactericidal effect that stops the spread of infection.

Regulatory References

Metronidazole - StatPearls - NCBI Bookshelf

Therapeutic Uses of Flagil

Flagil (Metronidazole) Therapeutic Uses

Quick Facts: Flagil Therapeutic Domains
* Management of certain anaerobic bacterial infections
Treatment of trichomoniasis caused by T. vaginalis*
* Management of acute intestinal amebiasis and amebic liver abscess
* Use in certain cases of giardiasis and bacterial vaginosis

Flagil is a prescription medication utilized to address a variety of infections caused by susceptible organisms. Its primary therapeutic domains involve the management of infections caused by certain anaerobic bacteria, which may affect areas such as the abdomen, skin, joints, and reproductive system.

The drug is also indicated for the treatment of confirmed protozoal infections. This includes the management of symptomatic and asymptomatic trichomoniasis, an infection caused by Trichomonas vaginalis. Additionally, Flagil is used in the regimen for acute intestinal amebiasis (amebic dysentery) and the related condition of amebic liver abscess.

Furthermore, the medication has a role in addressing other protozoal conditions, such as giardiasis, and is utilized for bacterial vaginosis in women. These applications constitute the established therapeutic uses for the medication.

Eligibility and Restrictions for Use

Contraindications

Use of Flagil (Metronidazole) is strictly prohibited in certain patient populations as defined by regulatory labeling. It is contraindicated in patients with a history of hypersensitivity to metronidazole or other nitroimidazole derivatives. The medicine must not be used in patients who have taken disulfiram within the last two weeks, or in those with Cockayne syndrome due to the risk of severe hepatotoxicity. Use is also contraindicated during the first trimester of pregnancy when treating trichomoniasis.

Conditional Use and Restrictions

Eligibility is conditional for populations with specific health conditions or physiological states. Patients with severe hepatic impairment are recommended to receive a reduced dosage due to impaired clearance. Individuals with Central Nervous System (CNS) diseases or blood dyscrasias require close monitoring and caution. The medicine must not be used concurrently with alcohol consumption, which must be avoided for at least three days following therapy completion.

Age and Physiological Status

Safety and efficacy are not established for all pediatric indications. In newborns and elderly patients, caution and potential dose adjustments are necessary. Use during the second and third trimesters of pregnancy is permitted only if clearly needed. Breastfeeding is not recommended during treatment and for a specified time afterward.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of metronidazole (Flagil) is defined by strict prohibitions and changes to drug metabolism and clearance.

Formal Contraindications and Restrictions

Co-administration with Disulfiram is strictly prohibited; metronidazole must not be administered within 14 days of Disulfiram intake due to the officially documented risk of acute psychotic reactions. Consumption of Alcohol or products containing Propylene Glycol is also prohibited during therapy and for a mandated period of at least one to three days after the final dose, based on the risk of a severe disulfiram-like reaction. Furthermore, use is contraindicated in patients with Cockayne Syndrome due to the high risk of fatal, irreversible liver failure.

Pharmacokinetic Interactions

Metronidazole officially inhibits the metabolism of Warfarin and other oral anticoagulants, leading to potentiation of their effect. Conversely, certain agents like Phenobarbital and Phenytoin increase the metabolism of metronidazole, causing a decreased serum concentration. Metronidazole also reduces the clearance of several substances, including Lithium, Ciclosporin, and the cytotoxic drugs Busulfan and 5-Fluorouracil, resulting in increased plasma levels and a higher risk of toxicity for those co-administered agents. An elevated risk of QT interval prolongation is officially documented when metronidazole is used with other medicines that also prolong the QT interval. In advanced hepatic impairment, clearance is substantially impaired, leading to significant drug accumulation.

Mechanism of Action

The mechanism of Metronidazole is defined by a unique process of selective toxicity, restricted to acting within susceptible microorganisms. This action is irreversible and operates across two main mechanistic domains: drug activation and lethal genetic damage.

Selective Activation by Anaerobic Metabolism

This domain covers the mandatory initiation of the drug's effect, focusing on its requirement for a low-oxygen environment and specific microbial enzymes (like nitroreductase) found in susceptible organisms. The inactive Metronidazole (a prodrug) must intercept the pathogen's electron transport chain to be chemically reduced. This chemical prerequisite limits the drug's cytotoxic potential to the interior of the target microorganism, demonstrating its mechanistic specificity.

Irreversible DNA Destruction and Pathogen Termination

This domain details the core lethal sequence. Once reduced, Metronidazole forms highly unstable and reactive nitro radical anions. These short-lived cytotoxic intermediates immediately bind to and cause strand breakage and structural fragmentation of the pathogen's DNA. This damage immediately impairs the pathogen's ability to replicate and repair itself, resulting in a rapid bactericidal and protozoacidal effect that terminates the proliferation of the microbial population.

Dosage and Administration Information

How to Use Flagyl (Metronidazole) — Administration Guidelines

Established protocols for Flagyl outline the methods for proper administration. The medicine is primarily available for Oral intake (tablets, capsules, and suspension) or as an Intravenous (IV) infusion.

Dosing and Frequency

Dosing regimens vary based on the specific condition but are typically defined in milligrams per kilogram (mg/kg) for IV and pediatric use, or as fixed doses (e.g., 250 mg to 750 mg) for oral forms. The medication is generally taken on a schedule of Once Daily (QDay), Twice Daily (BID), or Three Times Daily (TID). For certain infections, a high-dose Single Dose may be prescribed.

Component	Instruction Summary
Standard Oral Dose	Varies by regimen, typically 250 mg to 750 mg per dose.
IV Administration	Administered as a slow infusion over 30 to 60 minutes.

Administration Conditions

The way Flagyl is taken depends on the formulation:

Immediate-Release Forms: May be taken with food to help minimize stomach upset.
Extended-Release (ER) Tablets: Must be swallowed whole and not chewed, crushed, or broken. These must be taken on an empty stomach (e.g., 1 hour before or 2 hours after meals).

Special Use Guidelines

Hepatic Impairment: A reduced dose may be required for patients with severe liver disease to prevent accumulation of the drug and its metabolites.
Hemodialysis: A supplemental dose may be needed following a hemodialysis session, as the process removes a significant amount of the drug from the body.
Course Duration: The length of treatment is predefined for specific conditions, often ranging from 5 days to 10 days, and should not be extended without specific medical instructions.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flagil (Metronidazole)

Evidence for Use in Anaerobic Bacterial Infections

Research on metronidazole for conditions involving certain oxygen-intolerant bacteria was studied for complex infections, particularly those affecting the abdomen. These investigations primarily took the form of Randomized Controlled Trials (RCTs) and systematic reviews. In these trials, metronidazole was evaluated in combination with other antimicrobial agents, and research examined outcomes such as the resolution of clinical infection signs and symptoms (clinical success) and the rates of patient survival.

Findings describe patterns observed in the studies where metronidazole was included in a treatment regimen for hospitalized adults with severe infections. Studies monitored the disappearance of infection signs over short time intervals, such as during the treatment period itself. This evidence contributes to metronidazole's place in the broader evidence landscape, where it is studied for these conditions.

Evidence for Use in Protozoal Infections

Evidence for Trichomoniasis

Studies exploring metronidazole for trichomoniasis, a condition characterized by outcomes linked to inflammatory or irritative states, have largely consisted of RCTs. Research examined different ways of administering the medicine, such as single-dose versus multi-day regimens. The main focus of these studies was measuring parasitological clearance, which means the organism is no longer detectable, and clinical cure, defined as the observation of symptom change. Trials described patterns of parasitological clearance in the study populations. However, research highlights changes measured during the study period related to recurrence, with some studies indicating that recurrence was observed in some studies more frequently following single-dose regimens.

What is Still Uncertain About Flagil's Research Record

The research record for metronidazole is extensive, but still contains several gaps. Evidence is limited in determining optimal strategies for preventing recurrence in conditions like bacterial vaginosis, where high rates of relapse are still emerging as a key issue. Furthermore, comparative evidence is lacking in some areas, such as the direct comparison of metronidazole against newer classes of antibiotics for severe anaerobic infections. Most studies only compare metronidazole-based combination therapy to other forms of combination therapy. Finally, given that many key trials for older indications like amebiasis are decades old, data are still emerging from contemporary studies that use modern standards and longer follow-up times, meaning that certainty remains low regarding some aspects of its long-term performance.

Frequently Asked Questions (FAQ)

Common questions about Flagil (FAQ)

Q: What is Flagil used for?

According to the official product information, Flagil (metronidazole) is an antimicrobial agent used to treat infections caused by certain types of bacteria and parasites. It is commonly prescribed for specific gastrointestinal infections, infections of the reproductive tract, and infections affecting the skin, bone, or blood. The treatment is specific to infections caused by organisms susceptible to metronidazole.

Q: Can I drink alcohol while taking Flagil?

Regulatory documents state that consuming alcohol or products containing propylene glycol should be avoided while taking Flagil and for at least 3 days after stopping the treatment. The combination can lead to severe adverse reactions, including flushing, headache, nausea, and vomiting. This is often referred to as a disulfiram-like reaction.

Q: What happens if I miss a dose of Flagil?

The official product information addresses missed doses by generally advising to take the dose as soon as it is remembered, unless it is close to the time for the next scheduled dose. It also states that users should not take two doses at once to compensate for a missed dose. Specific instructions for handling a missed dose are provided on the official drug label and should be followed.

Q: Does Flagil affect the color of my urine?

Official information indicates that Flagil may cause a change in the color of your urine, often resulting in a reddish-brown color. This effect is a known and harmless consequence of the medication itself and typically reverses once the course of treatment is finished. It is not considered a cause for concern.

Q: Is Flagil an antibiotic?

Yes, Flagil, which contains the active ingredient metronidazole, is classified as an antibiotic and an antiprotozoal agent. It belongs to the nitroimidazole class of antimicrobials. It functions by targeting and inhibiting susceptible microorganisms, thus treating infections caused by both certain bacteria and parasites.

Q: How long do I need to take Flagil?

The length of time Flagil is taken is determined by the specific type and severity of the infection being addressed. Official product information indicates that treatment duration can range significantly, from a single dose for certain conditions to multi-week regimens for others. The regulatory information emphasizes the importance of following the prescribed regimen duration.

How should Flagil be stored and disposed of?

The official storage and disposal requirements for Flagyl (metronidazole) are defined by regulatory documents to maintain its stability and ensure safe handling.

Storage Requirement	Specification (Based on Regulatory Labeling)
Temperature Limit	Store below 86 F (30 C) for oral tablets. Oral capsules/solution require Controlled Room Temperature (e.g., 59 F to 77 F).
Environmental Protection	Oral tablets must be protected from light.
Child Safety	Keep out of reach of children is mandatory.
Post-Opening Stability	The oral solution must be discarded ten days after opening (stability may vary by formulation).
Disposal	Unused product and waste material must be disposed of in accordance with local requirements.

These conditions ensure the medicine remains chemically stable and is protected from temperature extremes and light exposure. Final disposal must comply with local regulatory guidelines for pharmaceutical waste.

Classification	Examples of Reactions
Very Common (ge 1/10)	Nausea, metallic or unpleasant taste.
Common (ge 1/100 to < 1/10)	Headache, dizziness, digestive issues (diarrhea, vomiting, abdominal pain), candidiasis.
Serious (Rare)	Encephalopathy, peripheral neuropathy (nerve damage), severe cutaneous adverse reactions (SJS/TEN), neutropenia (low white blood cell count).

Property	Official Regulatory Statement
Documented Manifestations	Nausea, vomiting, and ataxia (loss of muscle coordination) are symptoms reported following massive single oral doses of the drug.
Severe Outcomes	High-dose exposure is associated with neurotoxic effects, including convulsive seizures, peripheral neuropathy, and encephalopathy (abnormal brain function).
Specific Population Note	Patients with severe hepatic insufficiency are noted to be at risk for drug accumulation, which can contribute to the manifestation of encephalopathy due to impaired clearance.

Flagil